Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

c-GMP compliance of C-stem, an IPSc based cell therapies production technology

Project description

Technological production of GMP-compliant stem cells

Large-scale cell therapy manufacturing provides many opportunities including the possibility to replace failing tissues in patients suffering from incurable, chronic or degenerative diseases as well as the economic viability of the development of cell therapies for rare diseases. The cell therapy market is booming with thousands of clinical trials underway. However, the industrial production of human-induced pluripotent stem cells, which provide the raw material for cell therapies, is facing obstructions. Current manufacturing models do not meet the regulatory standards in terms of safety, cost, volume and lead time. The goal of the EU-funded C-stemGMP project is to develop within two years a 'good manufacturing practices' (GMP) compatible encapsulation device that can respond to market's needs in terms of scalability, quality and cost effectiveness.

Objective

Scaling-up cell therapy manufacturing provides many benefits: the capacity to replace failing tissues in patients suffering from incurable chronic or degenerative diseases, affordable treatments and the economic viability of the development of cell therapies for rare diseases. The baseline of TreeFrog Therapeutics (TFT), “Cell Therapy for All”, encapsulates this vision.TFT has already obtained outstanding results with its C-StemTM stem cell culture technology, fully scalable and allowing a high cell multiplication factor.
The cell therapy market has boomed since 2012. In 2018, 1,028 clinical trials were underway according to the Alliance for Regenerative Medicine and big pharmas invested €6.2bn in cell therapy programs. The FDA anticipates to approve « 10 to 20 cell and gene therapy products a year » by 2025.
A critical bottleneck remains for the cell therapies that will reach the market within 5 to 10 years: the industrial production of human induced pluripotent stem cells, the raw material for cell therapies. Current manufacturing models do not meet the standards of regulatory authorities and healthcare systems in terms of safety, cost, volume and lead time. With C-StemTM, TFT is in the best position to become the global supplier of stem cells for cell therapy’s industry.
Tailored for cost-killing mass-production of stem cells, while defining a new quality standard for cellular products, C-StemTM needs to be certified for “Good Manufacturing Practices” (GMP) to be used in clinical settings and capture its market. This project requires, within 24 months, to develop a GMP encapsulation device, to replace non-compliant materials, while developing relations with EU/US regulatory agencies and clients from the pharmaceutical industry.
TFT has a “go-global” strategy and aims at leading its market within 7 years. Funding from the H2020 Instrument PME Phase 2 would secure the project and consolidate TFT on the financial level, a key element to outpace non-european players.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

TREEFROG THERAPEUTICS
Net EU contribution
€ 2 367 998,00
Address
146 RUE LEO SAIGNAR BATIMENT
33000 BORDEAUX
France
SME
Yes
Region
Nouvelle-Aquitaine Aquitaine Gironde
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 382 855,00